First, although we confirmed the role of C1R in GBM across multiple datasets and cell lines, the high heterogeneity of GBM suggests significant variations among different tumor subtypes and individual patients, potentially affecting the universality of TEFT treatment and TGF‐β/C1R targeted therapy. This evidence concerns the gene C1R and neoplasm.